Placebo Control

It is a surprisingly common peril among analysts: we don’t have the data to answer the question we’re interested in, so we answer a related ...

Adam Feuerstein appears to be a generally astute observer of the biotech scene. As a finance writer, he's accosted daily with egregiou...

“Children are not small adults.” We invoke this saying, in a vague and hand-wavy manner, whenever we talk about the need to study drugs in p...

Results reporting requirements are pretty clear. Maybe critics should re-check their methods? Ben Goldacre has rather famously described t...

PDUFA V commitments signal a strong commitment to tolerance of open debate in the face of uncertainty. I can admit to a rather powerful la...

FDA should get out of the data entry business. There’s an app for that! We've all heard that more than enough times. It started as ...

Can you shed three years of pipeline flab with this one simple trick? "There’s no trick to it ... it’s just a simple trick!"  -...

No stones, please. Yesterday, Alec Gaffney was kind enough to ask my opinion on GSK's signing on to the AllTrials initiative to b...

Ben Goldacre – whose Bad Pharma went on sale today – is fond of using a coin-toss-cheating analogy to describe the problem of "hidde...

I am in the process of writing up a review of this rather terrible Forbes piece on the FDA recall of one manufacturer's version of gen...

An open letter to Mad Men producer/writer Dahvi Waller Dear Dahvi, I just wanted to drop you a quick note of congratulations when I hea...

* for some value of "most" ** for some value of "too" [Note: this is a companion to a previous post, Clouding the Deba...